Context Therapeutics (NASDAQ:CNTX) Earns Outperform Rating from William Blair

William Blair reaffirmed their outperform rating on shares of Context Therapeutics (NASDAQ:CNTX - Free Report) in a research note published on Tuesday morning,RTT News reports. William Blair also issued estimates for Context Therapeutics' Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.08) EPS and Q4 2026 earnings at ($0.07) EPS.

Other equities analysts also recently issued research reports about the stock. JMP Securities began coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They issued an "outperform" rating and a $4.00 target price for the company. HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a research report on Friday, March 21st. D. Boral Capital reiterated a "buy" rating and set a $9.00 price target on shares of Context Therapeutics in a research report on Tuesday. Finally, Citizens Jmp raised shares of Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, Context Therapeutics presently has a consensus rating of "Buy" and an average price target of $6.17.

Context Therapeutics Price Performance

Shares of NASDAQ CNTX traded up $0.01 during mid-day trading on Tuesday, reaching $0.87. 30,000 shares of the company's stock were exchanged, compared to its average volume of 303,796. Context Therapeutics has a 52 week low of $0.55 and a 52 week high of $2.75. The firm has a 50-day moving average price of $0.78 and a two-hundred day moving average price of $1.17. The firm has a market capitalization of $78.01 million, a price-to-earnings ratio of -0.96 and a beta of 2.18.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last issued its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. As a group, sell-side analysts forecast that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Context Therapeutics

A number of large investors have recently added to or reduced their stakes in CNTX. MPM Bioimpact LLC purchased a new stake in Context Therapeutics in the fourth quarter worth approximately $15,441,000. Franklin Resources Inc. lifted its stake in Context Therapeutics by 115.9% in the fourth quarter. Franklin Resources Inc. now owns 4,003,380 shares of the company's stock worth $4,204,000 after purchasing an additional 2,149,392 shares during the last quarter. Allostery Investments LP bought a new position in shares of Context Therapeutics during the fourth quarter valued at about $998,000. Blue Owl Capital Holdings LP lifted its stake in shares of Context Therapeutics by 17.5% in the 4th quarter. Blue Owl Capital Holdings LP now owns 6,357,928 shares of the company's stock valued at $6,676,000 after acquiring an additional 946,638 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in Context Therapeutics by 412.8% during the 4th quarter. Renaissance Technologies LLC now owns 338,435 shares of the company's stock valued at $355,000 after acquiring an additional 272,435 shares during the period. Hedge funds and other institutional investors own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.